Ledipasvir 33.75 mg / sofosbuvir 150 mg per packet Oral Pellets
RxNorm 2204100

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2204100 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ledipasvir 33.75 mg / sofosbuvir 150 mg per packet Oral Pellets.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
Ledipasvir 33.75 mg / sofosbuvir 150 mg Oral Pellet
Primary clinical definition
AUI:11454035
View
PSN
Ledipasvir 33.75 mg / sofosbuvir 150 mg per packet Oral Pellets
AUI:11454040
View
PT
Ledipasvir 33.75 mg and sofosbuvir 150 mg oral granules sachet
AUI:12871805
View
FN
Product containing precisely ledipasvir 33.75 mg and sofosbuvir 150 mg/1 sachet conventional release oral granules (clinical drug)
AUI:12872136
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDPrescribable

Semantic Clinical Drug (SCD):
Ledipasvir 33.75 mg / sofosbuvir 150 mg Oral Pellet
(Atom ID: 11454035)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
ledipasvir 33.75 MG / sofosbuvir 150 MG Oral Pellet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2204100
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11454035
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
2204100
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2203990} 1484911
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{2204099} 1591922
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2203990} 1484911
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{2204099} 1591922
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
33.75 MG / 150 MG
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{2203990} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{2204099} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
PSNPrescribable

Prescribable Name (PSN):
Ledipasvir 33.75 mg / sofosbuvir 150 mg per packet Oral Pellets
(Atom ID: 11454040)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
ledipasvir 33.75 MG / sofosbuvir 150 MG per packet Oral Pellets
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2204100
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11454040
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2204100
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
PTPrescribable

Designated preferred name (PT):
Ledipasvir 33.75 mg and sofosbuvir 150 mg oral granules sachet
(Atom ID: 12871805)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Ledipasvir 33.75 mg and sofosbuvir 150 mg oral granules sachet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2204100
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12871805
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
1118341000202109
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
FNPrescribable

Full form of descriptor (FN):
Product containing precisely ledipasvir 33.75 mg and sofosbuvir 150 mg/1 sachet conventional release oral granules (clinical drug)
(Atom ID: 12872136)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing precisely ledipasvir 33.75 milligram and sofosbuvir 150 milligram/1 sachet conventional release oral granules (clinical drug)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2204100
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12872136
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
1118341000202109
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.

Patient Education

Ledipasvir and Sofosbuvir


The combination of ledipasvir and sofosbuvir is used alone or in combination with ribavirin (Copegus, Rebetol, Ribasphere, others) to treat certain types of chronic hepatitis C (an ongoing viral infection that damages the liver) in adults and children 3 years of age and older. Sofosbuvir is in a class of antiviral medications called nucleotide polymerase inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Ledipasvir is in a class of antiviral medications called HCV NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body.
[Learn More]


* Please review the disclaimer below.